Editorial: mRNA Vaccines and Immunotherapy in Oncology: A New Era for Personalized Medicine

Parums, Dinah V.

doi:10.12659/msm.933088

Cited by 4 publications

(2 citation statements)

References 10 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The speed and potential cost gains of mRNA technology make it an interesting technology for personalized medicine. It is possible to take tumor tissue samples and develop mRNA vaccines that result in the expression of tumor antigens [26]. Many companies are working on integrated system mRNA processing solutions for this, such as CureVac with an mRNA printer and companies pursuing plug and play approaches like Nutcracker Therapeutics [24].…”

Section: New Modality For Cancer Treatmentmentioning

confidence: 99%

Discovery to delivery in 100 days: RNA therapeutics & their role in future pandemic preparedness

Humphries¹

2022

Vaccine Insights

View full text Add to dashboard Cite

Recently, the Coalition Epidemic Preparedness Innovations (CEPI) announced their ambition to develop vaccines against emerging diseases in 100 days. mRNA vaccines are a manufacturing modality that is suited to meet the 100-day strategy. The technology offers great benefits and potential for infectious diseases and personalized medicines due to the advantages in flexibility, cost, and speed of development, but there are still challenges to overcome to fully realize the potential. How can manufacturers prepare for rapid response?

show abstract

Section: New Modality For Cancer Treatmentmentioning

confidence: 99%

Discovery to delivery in 100 days: RNA therapeutics & their role in future pandemic preparedness

Humphries¹

2022

Vaccine Insights

View full text Add to dashboard Cite

show abstract

“…Selpercatinib monotherapy is now indicated for the treatment of advanced RET-mutant MTC in adults [ 10 ]. The authors present a case of a 60-year-old male diagnosed with cervical lymph nodes, liver, and lung metastases of medullary thyroid carcinoma in 2018 who underwent surgery (R1) with two previous lines of treatment with vandetanib and cabozantinib.…”

Section: Introductionmentioning

confidence: 99%

Innovation and Precision Medicine Applied to a Medullary Thyroid Cancer: A Clinical Case

Guedes¹,

Leão²,

Soares³

et al. 2023

Cureus

View full text Add to dashboard Cite

Medullary thyroid carcinoma (MTC) is a rare type of neuroendocrine tumor, accounting for 3%-4% of all thyroid cancers. Seventy-five percent are sporadic, of which 60% have pathogenic REarranged during Transfection (RET) somatic mutations. The sporadic RET-mutated MTC poses novel challenges for targeted treatment. The authors present a case of a 60-year-old male diagnosed in 2018 with MTC who underwent total thyroidectomy with sternotomy and bilateral cervical lymph node dissection - pT3N1b R1 L1 V1 Pn0 cM1 (hepatic and lung metastasis). According to the decisions made by the multidisciplinary tumor board, the patient received multiple palliative systemic treatments. Despite an initial response, vandetanib was accompanied by grade 3 high blood pressure and progression after 14 months of treatment. The patient also received cabozantinib, which led to an initial response, but with grade 3 hypertension and skin toxicity. The patient progressed, including symptomatic bone metastasis, after 15 months of treatment. Following the next sequencing genome result, which showed a somatic mutation in the RET M918T gene, the patient was treated with selpercatinib, a highly selective and potent RET inhibitor. The treatment led to clinical and radiological responses without significant toxicities. The objective of this case report is to highlight the impact of innovative treatment and precision medicine on the management of cancer patients, which not only has a direct effect on their survival but also on their quality of life.

show abstract

Cancer nanotechnology: current status and perspectives

2021

View full text Add to dashboard Cite

Modern medicine has been waging a war on cancer for nearly a century with no tangible end in sight. Cancer treatments have significantly progressed, but the need to increase specificity and decrease systemic toxicities remains. Early diagnosis holds a key to improving prognostic outlook and patient quality of life, and diagnostic tools are on the cusp of a technological revolution. Nanotechnology has steadily expanded into the reaches of cancer chemotherapy, radiotherapy, diagnostics, and imaging, demonstrating the capacity to augment each and advance patient care. Nanomaterials provide an abundance of versatility, functionality, and applications to engineer specifically targeted cancer medicine, accurate early-detection devices, robust imaging modalities, and enhanced radiotherapy adjuvants. This review provides insights into the current clinical and pre-clinical nanotechnological applications for cancer drug therapy, diagnostics, imaging, and radiation therapy.

show abstract

Editorial: mRNA Vaccines and Immunotherapy in Oncology: A New Era for Personalized Medicine

Cited by 4 publications

References 10 publications

Discovery to delivery in 100 days: RNA therapeutics & their role in future pandemic preparedness

Discovery to delivery in 100 days: RNA therapeutics & their role in future pandemic preparedness

Innovation and Precision Medicine Applied to a Medullary Thyroid Cancer: A Clinical Case

Cancer nanotechnology: current status and perspectives

Contact Info

Product

Resources

About